JACKSONVILLE, Fla., June 26, 2008 (PRIME NEWSWIRE) -- BodyTel Scientific Inc. (OTCBB:BDYT), a developer and manufacturer of wireless telemedical devices, announces today that it has, through its wholly owned subsidiary BodyTel Europe GmbH, entered into an exclusive distribution agreement with Sanisa of Valencia, Spain. Beginning in the third quarter of 2008, BodyTel's new partner, Sanisa, will begin offering BodyTel's blood glucose monitoring and diabetes management system, GlucoTel(tm), in Spain and Portugal. Pursuant to the terms of the distribution agreement, BodyTel granted Sanisa the right to exclusively market GlucoTel in those countries for a term of one year.
Angel Garcia Tellez, Sales Director of Sanisa, stated, "Medical device companies and pharmaceutical companies are constantly introducing new products to assist people with diabetes, but no recent innovations in this field have adequately addressed information management and data archiving. Taking into account that in Spain and Portugal there are an estimated three and a half million people with diabetes and the scientific community estimates this number to double over the next 15 years, it is easy to realize that we are talking about a very sizable market and exciting business opportunity. BodyTel offers patients with diabetes a new alternative compared with everything developed so far in autonomy, operability, reliability, and tranquility. GlucoTel is a wonderful tool for self-management."
"Headquartered in Valencia, Spain, Sanisa is operated by a dedicated team of marketing and business development advisors," stated Stefan Schraps, CEO of BodyTel. "Focused on new technologies in the medical-scientific arena, Sanisa's advisors have a breath of knowledge and experience in the diabetes sector. They are a perfect partner to introduce our diabetes management solution within Spain and Portugal."
The GlucoTel system is a complete telemedical blood glucose monitoring and diabetes management system, supporting patients and healthcare professionals in the treatment and control of diabetes and other associated disorders. GlucoTel electronically measures the blood sugar level and sends it automatically via Bluetooth to the patient's cell phone. Measured values are automatically transmitted from the cell phone to BodyTel's online database via mobile internet connection and stored on a long-term basis in the patient's secured profile. To facilitate better diabetes management, the patient and any authorized persons, e.g. healthcare professionals or other caregivers, can access the database 'BodyTel Center' at www.bodytel.com via the Internet at any time using a secure login.
The GlucoTel system is the first system of its kind that can provide real-time monitoring and management through its optional alarm functions. If defined by the caregiver, the BodyTel Center can create an alert message (e.g. via text message or email) that can be sent to caregivers informing them immediately of a potential out-of-range result or other unusual behavior like not performing any test within a predefined time frame. The versatility of the system provides all these tools, but use is completely optional and can be enabled or disabled, based on patient, caregiver or healthcare professional requirements, preventing possible serious complications if action is taken without delay.
About BodyTel
BodyTel is a German-American telehealth company that specializes in telemedical monitoring and management systems for chronic diseases. The company combines its know-how in telecommunications, Internet and medical technology/diagnostics to create new products and services for the changing needs of global health. BodyTel products are designed not only to simplify home monitoring by patients, but also to ease the communication of measured body values to healthcare professionals or other caregivers by bridging the gap between the patient and the caregivers instantaneously and in real-time. BodyTel's products -- GlucoTel, PressureTel and WeightTel -- are each at different stages of development and approval processes. Further information can be found at www.bodytel.com.
Forward-Looking Statements
Statements in this news release that are not historical are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "aims," "potential," "goal," "objective," "prospective," and similar expressions, or that events or conditions "will," "would," "may," "can," "could" or "should" occur. Forward-looking statements in this news release include: BodyTel's new partner, Sanisa, will begin offering BodyTel's blood glucose monitoring and diabetes management system, GlucoTel in Spain and Portugal, and they are a perfect partner to introduce our diabetes management solution within Spain and Portugal. It is important to note that the Company's actual outcomes may differ materially from those statements contained in this press release. Factors which may delay or prevent these forward looking statements from being realized include, but are not limited to those concerning the timing of regulatory approval or commercialization of its products or the achievement of any other clinical, regulatory or product development milestones or other risk factors and matters set forth in the Company's Annual Report on Form 10-KSB for the year ended February 28, 2007 and the Company's periodic reports filed with the SEC. These reports are available on our investor relations website at www.bodytel.com and on the SEC's website at http://www.sec.gov. BodyTel undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.